|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0278 USD | +969.23% |
|
-.--% | +77.07% |
| 05-26 | Trivarx Limited Announces Change of Registered Office | CI |
| 03-05 | TrivarX Limited Announces Executive Changes | CI |
| Market Cap | 24.23M 16.95M 14.73M 13.76M 12.63M 23.81M 1.62B 162M 63.53M 806M 63.68M 62.27M 2.66B | P/E 2024 |
-5.79x | P/E 2025 | -4.2x |
|---|---|---|---|---|---|
| Enterprise Value | 23.15M 16.2M 14.08M 13.14M 12.07M 22.75M 1.54B 155M 60.7M 770M 60.85M 59.5M 2.54B | EV / Sales 2024 |
10.6x | EV / Sales 2025 | 3.76x |
| Free-Float |
74.67% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +969.23% | ||
| 1 month | +969.23% | ||
| 3 months | +1,012.00% | ||
| 6 months | +1,012.00% | ||
| Current year | +77.07% |
| 1 month | 0.03 | 0.03 | |
| Current year | 0 | 0.03 | |
| 1 year | 0 | 0.03 | |
| 3 years | 0 | 0.03 | |
| 5 years | 0 | 0.26 | |
| 10 years | 0 | 7.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Danielle Meyrick
CEO | Chief Executive Officer | - | 01/06/2026 |
Kai Sun
COO | Chief Operating Officer | - | 01/01/2023 |
Nova Taylor
SEC | Corporate Secretary | - | 01/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
David Trimboli
CHM | Chairman | - | 26/10/2022 |
| Director/Board Member | - | 15/02/2023 | |
Tony Keating
BRD | Director/Board Member | - | 29/07/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +969.23% | -.--% | - | - | 12.96M | ||
| -2.48% | -2.66% | +59.38% | +20.38% | 322B | ||
| -0.49% | +0.49% | +31.65% | -13.19% | 71.6B | ||
| -0.10% | +1.36% | +37.67% | +96.18% | 9.79B | ||
| -1.53% | -3.92% | -2.67% | -7.72% | 8.39B | ||
| -0.76% | -2.73% | -16.42% | -13.85% | 4.3B | ||
| +0.14% | -1.74% | -34.69% | +6.15% | 3.81B | ||
| -2.35% | -3.72% | -14.99% | +13.09% | 3.58B | ||
| +6.51% | +3.43% | +31.15% | +52.56% | 2.59B | ||
| +0.47% | +10.40% | +0.22% | -2.76% | 2.25B | ||
| Average | +97.18% | +0.44% | +10.14% | +16.76% | 47.54B | |
| Weighted average by Cap. | -1.59% | -0.03% | +50.32% | +15.49% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 889K 622K 541K 505K 463K 874K 59.29M 5.95M 2.33M 29.56M 2.34M 2.28M 97.52M | 1.03M 722K 627K 585K 537K 1.01M 68.77M 6.9M 2.7M 34.3M 2.71M 2.65M 113M |
| Net income | -1.43M -1M -873K -815K -748K -1.41M -95.69M -9.61M -3.76M -47.72M -3.77M -3.69M -157M | -943K -660K -574K -536K -492K -927K -62.91M -6.32M -2.47M -31.37M -2.48M -2.42M -103M |
| Net Debt | -832K -582K -506K -472K -434K -818K -55.5M -5.57M -2.18M -27.68M -2.19M -2.14M -91.29M | -1.08M -754K -656K -612K -562K -1.06M -71.89M -7.22M -2.83M -35.85M -2.83M -2.77M -118M |
Employees
6
Sector
Pharmaceuticals
- Stock Market
- Stocks
- TRI Stock
- MDBIF Stock
Select your edition
All financial news and data tailored to specific country editions
















